Argenx
ARGX
#465
Rank
A$76.47 B
Marketcap
A$1,228
Share price
2.39%
Change (1 day)
18.04%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): A$13.55

According to Argenx 's latest financial reports the company's current EPS (TTM) is A$13.24. In 2024 the company made an earnings per share (EPS) of A$20.77 an increase over its 2023 EPS that were of A-$7.70.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$13.55-34.79%
2024A$20.77-369.77%
2023A-$7.70-60.46%
2022A-$19.4763.33%
2021A-$11.92-40.37%
2020A-$20.00183.47%
2019A-$7.05123.09%
2018A-$3.1654.93%
2017A-$2.0414.07%
2016A-$1.7913.05%
2015A-$1.58-36.34%
2014A-$2.49209.04%
2013A-$0.80-33.99%
2012A-$1.22185.59%
2011A-$0.43